Home > Healthcare > Medical Devices > Operating Room Supplies > Fluorescence Guided Surgery Systems Market
Fluorescence Guided Surgery Systems Market Size
The fluorescence guided surgery systems market size was valued at around USD 101.3 million in 2023 and is estimated to grow at 14.1% CAGR from 2024 to 2032. Fluorescence-guided surgery (FGS) systems are advanced imaging systems used during surgical procedures to visualize and distinguish tissues with the help of fluorescent dyes.
In FGS, a surgeon injects a fluorescent dye that selectively binds to specific tissues, such as tumors. Special cameras and imaging systems then detect the fluorescence, creating a visual contrast that allows the surgeon to identify and remove targeted tissues with higher precision. Chronic conditions such as cancer and cardiovascular diseases are rising globally, leading to a higher demand for advanced diagnostic and surgical technologies.
For instance, according to the International Agency for Research on Cancer (IARC) 2022 report, among 20 million new cancer cases worldwide, lung cancer and female breast cancer are the most common, representing 12.4% and 11.6% of cases, respectively. They are followed by colorectal cancer (9.6%), prostate cancer (7.3%), and stomach cancer (4.9%).
Report Attributes | Details |
---|---|
Base Year: | 2023 |
Market Size in 2023: | USD 101.3 Million |
Forecast Period: | 2024 – 2032 |
Forecast Period 2024 – 2032 CAGR: | 14.1% |
2024 – 2032 Value Projection: | USD 330.7 Million |
Historical Data for: | 2021 – 2023 |
No. of Pages: | 145 |
Tables, Charts & Figures: | 189 |
Segments covered: | Type, Surgery, Application, End Use, & Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
Fluorescence Guided Surgery Systems Market Trends
Government initiatives aimed at improving surgical infrastructure significantly propel the demand for fluorescence guided surgery systems. These initiatives often include funding for advanced medical technologies, upgrading surgical facilities, and promoting the adoption of innovative tools to enhance surgical outcomes.
- For instance, in July 2024, OnLume Inc. received a substantial USD 2 million Phase II Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health (NIH)'s National Cancer Institute (NCI).
- This grant supported the advancement of OnLume's innovative FGS system. The funding aimed to facilitate further refinement of the device, enhancing intraoperative visualization of small lymphatic tissues and blood vessels, improving surgical precision and patient outcomes.
Fluorescence Guided Surgery Systems Market Analysis
Based on type, the market is segmented into SPY system, PDE system, VS3 iridium system, and other types. The SPY system segment dominated the market in 2023, accounting for a market share of 38.1% and a CAGR of 15%.
- The SPY system is highly prominent among the fluorescence guided surgery systems due to its advanced imaging capabilities and its impact on surgical precision.
- This system mainly utilizes ICG fluorescence imaging to provide real-time visualization of blood flow and tissue perfusion during surgery. This capability is crucial for improving surgical outcomes by allowing surgeons to accurately assess the viability of tissues, identify critical structures, and make informed decisions during procedures.
- The system's effectiveness in various surgical fields, including oncology and vascular surgery, enhances its market presence. Its integration into surgical workflows and its ability to reduce complications and improve patient outcomes contribute significantly to its prominence in the FGS market, making it a preferred choice among healthcare providers.
Based on surgery, the fluorescence guided surgery systems market is segmented into open surgery and laparoscopic/endoscopic surgery. Open surgery dominated the global market in 2023, with a market share of 54.2%.
- Open surgery's prominence can be attributed to its necessity in complex and extensive surgical procedures.
- Fluorescence guided surgery systems using advanced fluorescence contrast agents provide critical real-time visualization of tumors and surrounding tissues during open surgeries.
- This enhanced imaging capability enables surgeons to accurately identify and remove malignant tissues, improving surgical precision and reducing the risk of residual disease.
- Reported in several research studies, in open surgery, where comprehensive access to the surgical site is required, fluorescence guided surgery systems facilitate better delineation of anatomical structures and tumor boundaries, which is essential for successful outcomes.
Based on application, the fluorescence guided surgery systems market is segmented into cancer surgeries, cardiovascular surgeries, and other applications. The cancer surgeries segment is anticipated to reach USD 190.2 million by 2032.
- Fluorescence guided surgery systems use specialized fluorescence imaging to highlight cancerous tissues during surgery, enabling surgeons to make more accurate and informed decisions.
- This is particularly important in complex cancer procedures where distinguishing between malignant and healthy tissues can be challenging. The growing adoption of fluorescence guided surgery systems in cancer surgeries is driven by their ability to enhance surgical precision, reduce recurrence rates, and improve patient recovery times.
- For instance, a 2022 study in the Journal of Clinical Oncology examined fluorescence guided surgery systems for epithelial ovarian cancer using pafolacianine and intraoperative near-infrared (NIR) imaging. This Phase 3 trial involved 109 participants that showed the NIR fluorescence improved tumor detection beyond what is visible with standard white light. The technology's application could benefit newly diagnosed, post-chemotherapy, and recurrent ovarian cancer patients, enhancing treatment opportunities.
Based on end use, the fluorescence guided surgery systems market is segmented into hospitals and clinics, oncology centers, ambulatory surgery centers, and other end users. Hospitals and clinics held a prominent share in the market accounting for 51.7% in 2023.
- Their dominance was asserted due to their central position in delivering advanced surgical care. As these facilities are the primary settings where complex surgeries require precision and real-time visualization, they play a pivotal role in the market.
- With the growing prevalence of chronic diseases and increased surgical volumes, hospitals and clinics are actively focusing on optimizing a full spectrum of surgeries, from common procedures to complex ones, by integrating fluorescence guided surgery systems into their surgical suites to enhance patient care.
The U.S. dominated the North American fluorescence guided surgery systems market with the largest revenue of USD 38.4 million in 2023.
- The U.S. is a leader in medical technology innovation, with a strong emphasis on research and development. This results in the creation of advanced FGS systems with enhanced imaging capabilities and new fluorescent agents.
- Furthermore, the prevalence of cancer in the U.S. drives demand for advanced surgical techniques, including FGS, as surgeons seek improved outcomes in these challenging areas.
The market in the UK is expected to experience significant and promising expansion from 2024 to 2032.
- The UK has a well-established National Health Service (NHS) that facilitates the integration of advanced surgical technologies into clinical practice. This allows for widespread testing and implementation of FGS systems in various surgical specialties.
- The UK is home to numerous leading universities and research institutions that are at the forefront of medical technology innovation. This fosters collaboration between academia and industry, driving advancements in fluorescence imaging and surgical techniques.
Japan's fluorescence guided surgery systems market is anticipated to witness lucrative growth between 2024 and 2032.
- Japan has one of the world's fastest-aging populations, leading to an increased demand for advanced surgical solutions to treat age-related conditions. FGS systems can improve surgical outcomes and minimize recovery times, aligning with the needs of this demographic.
- The Japanese government actively promotes innovation in the healthcare sector through funding and research initiatives. Programs aimed at enhancing medical technology development provide financial support and encourage collaboration between industry and academia.
The market in Saudi Arabia is expected to experience significant and promising progression from 2024 to 2032.
- The Saudi government has made significant investments in healthcare infrastructure as part of its Vision 2030 initiative, which aims to enhance the quality and accessibility of healthcare services. This includes the modernization of hospitals and the integration of advanced medical technologies, such as FGS systems.
- There is a growing trend towards minimally invasive surgical techniques in Saudi Arabia, driven by patient preferences for shorter recovery times and reduced surgical risks. FGS systems align well with this trend, enhancing visualization and precision during surgeries.
Fluorescence Guided Surgery Systems Market Share
The fluorescence-guided surgery systems market is highly competitive, characterized by a mix of leading global manufacturers and smaller to medium-sized enterprises vying for market share. A critical aspect of market strategy involves the continuous introduction of innovative imaging technologies and surgical instruments, such as advanced fluorescence agents and real-time imaging systems. Prominent industry leaders significantly influence the market, often driving advancements through substantial investments in research and development.
Additionally, mergers, acquisitions, and strategic partnerships are crucial for consolidating market positions and expanding global reach in response to evolving surgical practices and regulatory frameworks. The growing emphasis on minimally invasive procedures, enhanced surgical outcomes, and patient safety continues to shape the competitive landscape, influencing product offerings and healthcare providers' trust in fluorescence-guided surgery systems.
Fluorescence Guided Surgery Systems Market Companies
Some of the eminent market participants operating in the fluorescence guided surgery systems industry include:
- B. Braun
- Carl Zeiss
- Danaher Corporation
- Getinge
- Hamamatsu Photonics
- Intuitive Surgical
- KARL STORZ
- Medtronic
- Olympus Corporation
- OnLume
- Shimadzu Corporation
- Stryker Corporation
- Samvardhana Motherson International
- Sumitomo Mitsui Financial Group
Fluorescence Guided Surgery Systems Industry News:
- In January 2024, Leica Microsystems, a subsidiary of Danaher, unveiled the ARveo 8. This new system elevates surgical visualization through its 3D perspective and Augmented Reality (AR) fluorescence. This strategy solidifies Leica's standing as a frontrunner in advanced surgical imaging and bolsters its competitive edge in the market.
- In May 2023, B. Braun launched its latest laparoscopic AESCULAP EinsteinVision 3.0 FI, featuring 3D Fluorescence Imaging (FI) with three overlay modes for real-time imaging. This advanced technology enhances surgical outcomes by providing improved diagnostic and procedural accuracy, benefiting the company by reinforcing its position in the market with advanced imaging solutions.
The fluorescence guided surgery systems market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:
Click here to Buy Section of this Report
Market, By Type
- SPY system
- Photo Dynamic Eye (PDE) system
- VS3 iridium system
- Other types
Market, By Surgery
- Open surgery
- Laparoscopic/endoscopic surgery
Market, By Application
- Cancer surgeries
- Cardiovascular surgeries
- Other applications
Market, By End Use
- Hospitals and clinics
- Ambulatory surgery centers
- Oncology centers
- Other end users
The above information is provided for the following regions and countries:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Netherlands
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Middle East and Africa
- Saudi Arabia
- South Africa
- UAE
Frequently Asked Questions (FAQ) :